Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Passes Above Fifty Day Moving Average of $10.02

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.02 and traded as high as $17.50. Pieris Pharmaceuticals shares last traded at $17.39, with a volume of 28,006 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Pieris Pharmaceuticals in a research report on Friday, July 12th. They issued a “hold” rating on the stock.

Pieris Pharmaceuticals Price Performance

The firm has a market capitalization of $22.95 million, a P/E ratio of -1.46 and a beta of 0.68. The stock’s 50 day moving average is $10.16 and its two-hundred day moving average is $12.11.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) EPS for the quarter. The firm had revenue of $0.05 million during the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 57.57%.

Institutional Trading of Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned approximately 0.14% of Pieris Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.